ABG Oxidative Stress Study Protocol-1

NCT ID: NCT02213523

Last Updated: 2014-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a proof of concept study that evaluates the response to oxidative stress in healthy men after taking plant concentrates.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sustained oxidative stress may cause hypertension, insulin resistance, metabolic syndrome, cardiovascular disease and other chronic conditions. Diets rich in natural antioxidants is associated with protective effects on the investigators health. The strategy to prevent chronic disease development and in making up the nutritional gap in the investigators diet has shifted from vitamins and minerals supplementation to whole foods and whole food products.

The objectives is to evaluate the effect of oxidative stress response of plant concentrate blends. Also, we'll confirm that vitamins, minerals and plant concentrates will not influence the biomarker expression that were monitored in the oxidative stress biomarkers. Lastly, collecting additional information on whether blends of plant concentrate have other potential health benefits.

This study will test the dose-response of blends of plant concentrates. Healthy men (n=60) with low fruit and vegetable intake will participate in a 32 day or 46 days. Each treatment duration lasts 14 days. Microarray assay and real time-polymerase chain reaction will be performed.Genes associated with oxidative stress will me monitored. The outcome of this study will help us understand how to design and develop future antioxidant related products.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plant concentrate A

Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)

Group Type EXPERIMENTAL

Plant concentrate A

Intervention Type DIETARY_SUPPLEMENT

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Plant concentrate B

Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)

Group Type EXPERIMENTAL

Plant concentrate B

Intervention Type DIETARY_SUPPLEMENT

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Plant concentrate C

Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)

Group Type EXPERIMENTAL

Plant concentrate C

Intervention Type DIETARY_SUPPLEMENT

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Plant concentrate D

Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)

Group Type EXPERIMENTAL

Plant concentrate D

Intervention Type DIETARY_SUPPLEMENT

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plant concentrate A

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention Type DIETARY_SUPPLEMENT

Plant concentrate B

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention Type DIETARY_SUPPLEMENT

Plant concentrate C

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention Type DIETARY_SUPPLEMENT

Plant concentrate D

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult men between 45-65 yr old with low fruit and vegetable intake
* Individual with low fruit and vegetable intake and consuming fewer than 12 items found on the Recommended Foods Check (RFC) (AppendixI) per week. (score \<12 pts)
* Individuals with screening blood and urine laboratory values within 20% of normal range indicated in the lab report (Appendix IV)
* Individual should be judged to be in good general health on the basis of an interview and abbreviated physical exam.
* Individual understands the procedures and agrees to participate in the study.
* Individual is willing to maintain their exercise habits and dietary pattern throughout the duration of the trial.
* Individual is willing to consume a diet or drink devoid of high content of quercetin (e.g. apple and onions), rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice thought the duration of the trial.
* Individual is able and willing to provide written informed consent and confidentiality agreement.

Exclusion Criteria

* Use of dietary supplements within one week of DAy 1. Supplements include any vitamins, minerals, and herbal products, including herbal drink.
* Presence of, or clinical significant history of, cancer, cardiovascular, endocrine, kidney, liver, lung, gastrointestinal, metabolic disorder, absorption disorder such as Celiae or Crohn's disease and/or any other chronic health condition such as diabetes identified from the finding of the interview.
* Presence of cardiovascular disease and hypertension with inconsistent medication regimen, unstable conditions, and without proper physician's supervision identified from the findings fo the interview.
* Individual who use medicines such as statins (e.g. simvastatin, fluvastatin), NSAIDS including aspirin, nitric oxide \*eNOS) activators or inhibitors (e.g. selegiline, Viagra), and angiotensin II receptor blocker (e.g. Telmisartan (blood pressure)), and take any of these medications within 10 hours prior to the blood and urine sample collection.
* Individuals who eat spicy food (e.g. capsaicin from chili pepper) and drink coffee and tea including herbal teas within 10 hours prior to the blood and urine sample collection.
* Participation in another clinical trial within 30 days of enrollment into the study.
* History of current abuse of nicotine, drugs or alcohol, or intake \>3 alcoholic beverages per day
* Have known allergy to the ingredients in the tested samples such as quercetin, rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice.
* Any condition that the principal Investigator believes amy put the subject under risk.
Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Access Business Group

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Keech, M.D.

Role: PRINCIPAL_INVESTIGATOR

Southbay Pharma Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Quality of Life

Buena Park, California, United States

Site Status

Southbay Pharma Research

Buena Park, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABG AOX-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Strong Women Study
NCT01476033 COMPLETED NA